ASTCT Clinical practice recommendations for transplant and cellular therapies in diffuse large B-cell lymphoma

• Published in: Transplantation and cellular therapy 2023-07
• Main Authors: Epperla, Narendranath, Kumar, Ambuj, Abutalib, Syed A, Awan, Farrukh T, Chen, Yi-Bin, Gopal, Ajay K, Holter-Chakrabarty, Jennifer, Kekre, Natasha, Lee, Catherine J, Lekakis, Lazaros, Lin, Yi, Mei, Matthew, Nathan, Sunita, Nastoupil, Loretta, Oluwole, Olalekan, Phillips, Adrienne A, Reid, Erin, Rezvani, Andrew R, Trotman, Judith, Zurko, Joanna, Kharfan-Dabaja, Mohamed A, Sauter, Craig S, Perales, Miguel-Angel, Locke, Frederick L, Carpenter, Paul A, Hamadani, Mehdi
• Format: Article
• Language: English
• ISSN: 2666-6367

Autologous hematopoietic cell transplantation (auto-HCT) has long remained the standard approach for patients with relapsed/refractory (R/R) chemosensitive diffuse large B-cell lymphoma (DLBCL). However, the advent of chimeric antigen receptor (CAR) T-cell therapy has caused a paradigm shift in the management of R/R DLBCL patients, especially with the recent approval of CD19-directed CAR T-cell therapy in the second line setting in high-risk groups (primary refractory and early relapse [≤12 months]). Consensus on the contemporary role, optimal timing, and sequencing of HCT and cellular therapies in DLBCL is lacking. Therefore, the American Society of Transplantation and Cellular Therapy (ASTCT) Committee on Practice Guidelines undertook this project to formulate consensus recommendations to address this unmet need. The RAND-modified Delphi method was used to generate 20 consensus statements with a few key statements as follows: 1) in the first-line setting, there is no role of auto-HCT consolidation for those achieving complete remission (CR) following R-CHOP or similar therapy in non-double hit/triple hit cases (DHL/THL) and in DHL/THL cases receiving intensive induction therapies, but auto-HCT may be considered in eligible patients receiving R-CHOP or similar therapies in DHL/THL cases. 2) Auto-HCT consolidation with thiotepa-based conditioning is standard-of-care for eligible patients with primary central nervous system achieving CR with first-line therapy. 3) In the primary refractory and early relapse setting, the preferred option is CAR T-cell therapy, while in late relapse (>12 months), consolidation with auto-HCT is recommended in those achieving chemosensitivity to salvage therapy (CR or partial response), and CAR T-cell therapy is recommended in those not achieving remission. These clinical practice recommendations will serve as a tool to guide clinicians managing patients with newly diagnosed and R/R DLBCL.